Zymeworks Inc.
ZYME Healthcare Biotechnology
Zymeworks Inc.’s revenue for fiscal 2025 (year ended December 2025) was $106.0 million, up 38.9% from fiscal 2024. In the quarter to June 2026, revenue fell 90.6%, EPS fell 2,166.7% and free cash flow fell 385.5%, each against the same quarter a year earlier.
Follow ZYME
Zymeworks Inc. (ZYME) EV/Sales
As of 16 October 2026, Zymeworks Inc. (ZYME) trades at a EV/Sales of 42.0×. Over the past ten years it has ranged from 0.1× (January 2023) to 92.8× (December 2020); the current reading is higher than 83% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 16.6× | 39.46% |
| FY2024 | 11.9× | 148.95% |
| FY2023 | 4.8× | 8,063.25% |
| FY2022 | 0.1× | (99.75%) |
| FY2021 | 23.4× | (53.58%) |
| FY2020 | 50.3× | 3.62% |
| FY2019 | 48.6× | 1,013.08% |
| FY2018 | 4.4× | 165.07% |
| FY2017 | 1.6× | (87.88%) |
| FY2016 | 13.6× | 0.00% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 44.1× | 138.13% |
| Mar 2026 | 18.5× | 11.72% |
| Dec 2025 | 16.6× | 109.42% |
| Sep 2025 | 7.9× | 41.67% |
| 38 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MLYS Mineralys Therapeutics, Inc. compare | n/m |
| SRPT Sarepta Therapeutics, Inc. compare | 1.0× |
| VIR Vir Biotechnology, Inc. compare | 3.7× |
| MRVI Maravai LifeSciences Holdings, Inc. compare | 5.3× |
| URGN Urogen Pharma compare | 9.7× |
| XNCR Xencor, Inc. compare | 13.4× |
| PVLA Palvella Therapeutics, Inc. compare | 35.6× |
| ZYME Zymeworks Inc. | 42.0× |
| MESO Mesoblast Limited compare | 137× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)